Management Team
Board of Directors
Investors
Careers
Scientific Background
References
Programs
PROGRAMS
Calithera plans to identify one or more caspase activators as development candidates and take them into Phase 1 clinical trials in cancer patients for proof-of-principle. In parallel, the company will expand its technology for targeting allosteric activating sites to other enzymes with therapeutic potential in cancer.